Please use this identifier to cite or link to this item: http://hdl.handle.net/1942/8276
Title: Tovaxin, radiation-attenuated, patient-specific T-cells for the therapeutic vaccination of multiple sclerosis
Authors: HELLINGS, Niels 
STINISSEN, Piet 
Issue Date: 2008
Publisher: THOMSON SCIENTIFIC
Source: CURRENT OPINION IN INVESTIGATIONAL DRUGS, 9(5). p. 534-540
Abstract: Opexa Pharmaceuticals Inc is developing Tovaxin, a trivalent formulation of attenuated myelin-peptide-reactive T-cells, for the potential treatment of multiple sclerosis. Tovaxin is being evaluated in phase II clinical trials. Opexa was previously investigating Tovaxin for the potential treatment of rheumatoid arthritis; however, no development has been reported for this indication since December 2002.
Notes: Hasselt Univ, Biomed Res Inst, B-3590 Diepenbeek, Belgium.
Document URI: http://hdl.handle.net/1942/8276
ISSN: 1472-4472
ISI #: 000255431300012
Category: A1
Type: Journal Contribution
Validations: ecoom 2009
Appears in Collections:Research publications

Files in This Item:
File Description SizeFormat 
Tovaxin.pdfNon Peer-reviewed author version107.36 kBAdobe PDFView/Open
Show full item record

WEB OF SCIENCETM
Citations

1
checked on Apr 24, 2024

Page view(s)

14
checked on Sep 7, 2022

Download(s)

2
checked on Sep 7, 2022

Google ScholarTM

Check


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.